TM
MLYS icon

Torren Management’s Mineralys Therapeutics MLYS Stock Holding History

Torren Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-39
Closed -$1.42K – 1261
2025
Q4 		$1.42K Buy
+39
New +$1.56K ﹤0.01% 1132

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Torren Management's MLYS Position: Q1 2026 in Review

Torren Management sold out of Mineralys Therapeutics (MLYS) in Q1 2026, closing a stake of 39 shares — an estimated $1.42K sold.

Torren Management first reported a position in MLYS in Q4 2025 and held it in 1 quarter. The position peaked at $1.42K in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Torren Management reported no remaining Mineralys Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Torren Management sold 39 Mineralys Therapeutics shares in Q1 2026, an estimated $1.42K.
  • Torren Management first reported a position in Mineralys Therapeutics in Q4 2025 and held it in 1 quarter.
  • Torren Management's Mineralys Therapeutics position peaked at $1.42K in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.